Family · Pharmaceutical analytical standards
Brexpiprazole
An atypical antipsychotic that modulates dopamine and serotonin receptors, approved in the United States in 2015 for schizophrenia and as add-on therapy in major depression. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?In 2023 it became the first medicine approved in the United States for agitation associated with Alzheimer's dementia, a symptom for which no medicine had previously been authorised.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
